These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 28043638)
21. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Shleeva MO; Kudykina YK; Vostroknutova GN; Suzina NE; Mulyukin AL; Kaprelyants AS Tuberculosis (Edinb); 2011 Mar; 91(2):146-54. PubMed ID: 21262587 [TBL] [Abstract][Full Text] [Related]
22. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492 [TBL] [Abstract][Full Text] [Related]
23. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Taneja NK; Tyagi JS J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560 [TBL] [Abstract][Full Text] [Related]
24. Extracellular Matrix-Induced GM-CSF and Hypoxia Promote Immune Control of Arbués A; Schmidiger S; Kammüller M; Portevin D Front Immunol; 2021; 12():727508. PubMed ID: 34603299 [TBL] [Abstract][Full Text] [Related]
26. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339 [TBL] [Abstract][Full Text] [Related]
27. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142 [TBL] [Abstract][Full Text] [Related]
28. Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis. Domingo-Gonzalez R; Das S; Griffiths KL; Ahmed M; Bambouskova M; Gopal R; Gondi S; Muñoz-Torrico M; Salazar-Lezama MA; Cruz-Lagunas A; Jiménez-Álvarez L; Ramirez-Martinez G; Espinosa-Soto R; Sultana T; Lyons-Weiler J; Reinhart TA; Arcos J; de la Luz Garcia-Hernandez M; Mastrangelo MA; Al-Hammadi N; Townsend R; Balada-Llasat JM; Torrelles JB; Kaplan G; Horne W; Kolls JK; Artyomov MN; Rangel-Moreno J; Zúñiga J; Khader SA JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978810 [TBL] [Abstract][Full Text] [Related]
29. Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs Pieterman ED; Sarink MJ; Sala C; Cole ST; de Steenwinkel JEM; Bax HI Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340993 [TBL] [Abstract][Full Text] [Related]
30. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Dickinson JM; Aber VR; Mitchison DA Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404 [TBL] [Abstract][Full Text] [Related]
31. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038 [TBL] [Abstract][Full Text] [Related]
33. Morphological changes in experimental tuberculosis resulting from treatment with quercetin and polyvinylpyrrolidone. Butova T; Zaitseva S; Butov D; Stepanenko G Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S103-S104. PubMed ID: 28043489 [TBL] [Abstract][Full Text] [Related]
34. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model. Rey-Jurado E; Tudó G; Soy D; González-Martín J Int J Antimicrob Agents; 2013 Dec; 42(6):524-30. PubMed ID: 24080479 [TBL] [Abstract][Full Text] [Related]
36. Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase. Khan SR; Singh S; Roy KK; Akhtar MS; Saxena AK; Krishnan MY Int J Antimicrob Agents; 2013 Jan; 41(1):41-6. PubMed ID: 23141113 [TBL] [Abstract][Full Text] [Related]
37. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model. Sarkar S; Sarkar D J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731 [TBL] [Abstract][Full Text] [Related]
38. A Fluorescent Probe for Detecting Yang D; Ding F; Mitachi K; Kurosu M; Lee RE; Kong Y Front Microbiol; 2016; 7():2021. PubMed ID: 28066347 [TBL] [Abstract][Full Text] [Related]
39. [A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis]. Lu Y; Wang B; Zhao WJ; Zheng MQ; Li P; Fu L; Liang BW Zhonghua Jie He He Hu Xi Za Zhi; 2010 Sep; 33(9):675-8. PubMed ID: 21092635 [TBL] [Abstract][Full Text] [Related]
40. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]